Answers are grounded in this paper and cite their sources.
Background Advanced ovarian carcinoma (OC) portends a dismal prognosis, particularly in the context of platinum-resistant or refractory disease. Despite a well-characterized immunogenic phenotype in a subset of tumors, the therapeutic efficacy of immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 or CTLA-4 axes remains equivocal. This meta-analysis was undertaken to quantitatively synthesize evidence from randomized controlled trials (RCTs) and elucidate the aggregate survival benefit of ICI-based regimens in advanced OC, with stratification by clinically relevant biomarkers and treatment contexts. Methods A systematic literature search was executed across PubMed/MEDLINE, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, and ClinicalTrials.gov from database inception through January 2025. Eligible studies were phase II or III RCTs that evaluated monoclonal antibodies targeting PD-1, PD-L1, or CTLA-4, administered as monotherapy or in combination with standard cytoreductive therapies, in adults with histologically confirmed advanced or recurrent OC. The primary efficacy endpoints were progression-free survival (PFS) and overall survival (OS), analyzed via pooled hazard ratios (HRs) with 95% confidence intervals (CIs) using a DerSimonian–Laird random-effects model. Secondary endpoints included objective response rate (ORR) and treatment discontinuation rates attributable to adverse events (AEs). Prespecified subgroup and sensitivity analyses interrogated effect modification by platinum sensitivity status, line of therapy, ICI mechanism of action, PD-L1 biomarker selection, and methodological quality. Where multi-arm trials shared a common control group, intervention arms were combined for the primary analysis, and a sensitivity analysis using single arms was performed to assess robustness. Results The analysis incorporated 13 RCTs encompassing approximately 6,400participants after removal of duplicate publications from the IMagyn050 trial. Aggregate data demonstrated no statistically significant improvement in PFS (pooled HR 1.00, 95% CI 0.88–1.13; p = 0.959), OS (pooled HR 0.92, 95% CI 0.85–1.01; p = 0.074), or ORR (pooled RR 1.01, 95% CI 0.94–1.09; p = 0.699) with ICI augmentation. Substantial heterogeneity was observed for PFS (I² = 68.7%), while OS and ORR showed low to moderate heterogeneity. Subgroup stratification identified a significant PFS benefit in the platinum-sensitive recurrent cohort (pooled HR 0.83, 95% CI 0.72–0.95; p = 0.009), whereas no benefit was observed in first-line (HR 0.99, 95% CI 0.80–1.22) or platinum-resistant (HR 1.09, 95% CI 0.88–1.35) settings. A significant OS benefit was observed in the recurrent setting (HR 0.88, 95% CI 0.79–0.98; p = 0.025), though this was based on only six trials. Trials judged to be at low risk of bias demonstrated a significant PFS advantage (HR 0.86, 95% CI 0.79–0.94; p for interaction = 0.013), though this finding was confounded by the concentration of platinum-sensitive trials in the low-risk stratum. A post-hoc correlation analysis revealed a significant inverse relationship between intervention-arm discontinuation rates and the magnitude of PFS benefit (Pearson’s r = − 0.611, p = 0.046); however, this association was likely attributable to trial-level confounding rather than a causal tolerability-exposure relationship, as control-arm discontinuation showed a similar correlation and the intervention-minus-control difference showed none. Conclusion The adjunctive use of immune checkpoint inhibitors does not confer a significant survival advantage in an unselected advanced ovarian cancer population. The certainty of evidence was LOW for PFS, downgraded for substantial heterogeneity, and MODERATE for OS and ORR. Our findings underscore the necessity for a precision oncology paradigm, with therapeutic benefit potentially restricted to molecularly defined, and platinum-sensitive recurrent disease subsets. The current evidence does not support the routine use of ICIs in unselected patients with advanced ovarian cancer. Future clinical development should prioritize biomarker-informed patient stratification, rational combinatorial strategies with PARP inhibition or antiangiogenic therapy, and rigorous management of immune-related adverse events (irAEs) to optimize therapeutic exposure and clinical outcomes. Clinical trial number Not applicable.
No takes yet. Share an insight, caveat, or question.
Kermanshahaninezhad et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: